Top-Rated StocksTop-RatedNASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free LEGN Stock Alerts $45.57 -0.99 (-2.13%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$45.48▼$46.9450-Day Range$39.50▼$57.2252-Week Range$38.60▼$77.32Volume965,307 shsAverage Volume1.39 million shsMarket Capitalization$8.31 billionP/E RatioN/ADividend YieldN/APrice Target$81.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Legend Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside78.0% Upside$81.10 Price TargetShort InterestBearish7.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 14 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.93) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.52 out of 5 starsMedical Sector431st out of 905 stocksPharmaceutical Preparations Industry200th out of 430 stocks 4.5 Analyst's Opinion Consensus RatingLegend Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLegend Biotech has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Legend Biotech's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.12% of the outstanding shares of Legend Biotech have been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Legend Biotech has recently decreased by 2.26%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LEGN. Previous Next 2.6 News and Social Media Coverage News SentimentLegend Biotech has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Legend Biotech this week, compared to 4 articles on an average week.Search Interest7 people have searched for LEGN on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($1.93) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -35.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -35.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 6.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Legend Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Augury ResearchBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is currently auctioning off CITGO (the winning bid will be announced on July 22nd).Get all the details here. About Legend Biotech Stock (NASDAQ:LEGN)Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Read More LEGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LEGN Stock News HeadlinesJune 7 at 7:28 AM | americanbankingnews.comLegend Biotech Co. Expected to Post FY2025 Earnings of $0.02 Per Share (NASDAQ:LEGN)June 5 at 3:56 AM | americanbankingnews.comLegend Biotech's (LEGN) Buy Rating Reaffirmed at HC WainwrightJune 3, 2024 | businesswire.comLegend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHAJune 2, 2024 | americanbankingnews.comLegend Biotech (NASDAQ:LEGN) Shares Down 6% May 29, 2024 | businesswire.comLegend Biotech to Participate in the Jefferies Global Healthcare ConferenceMay 29, 2024 | americanbankingnews.comLegend Biotech Co. (NASDAQ:LEGN) Receives Consensus Recommendation of "Buy" from AnalystsMay 26, 2024 | uk.investing.comLegend Biotech stock PT cut by H.C. Wainwright amid revenue slowdownMay 24, 2024 | msn.comDeutsche Bank Initiates Coverage of Legend Biotech Corporation - Depositary Receipt () (LEGN) with Buy RecommendationMay 23, 2024 | businesswire.comLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHAMay 22, 2024 | finanznachrichten.deMaxCyte, Inc: MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Singular Genomics Systems (OMIC)May 15, 2024 | msn.comLegend Biotech Corporation (NASDAQ:LEGN) Q1 2024 Earnings Call TranscriptMay 14, 2024 | markets.businessinsider.comBuy Rating for Legend Biotech Anchored by Carvykti’s Growth and Market Penetration PotentialMay 14, 2024 | markets.businessinsider.comLegend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)May 14, 2024 | seekingalpha.comLegend Biotech's Carvykti Faces Stiff Challenges Despite AdvancesMay 14, 2024 | finance.yahoo.comLegend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript Highlights: Soaring CARVYKTI Sales ...May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Legend Biotech on CARVYKTI Growth and Positive Clinical DevelopmentsMay 14, 2024 | finance.yahoo.comQ1 2024 Legend Biotech Corp Earnings CallMay 13, 2024 | marketwatch.comLegend Biotech 1Q Loss Narrows with Higher Carvykti SalesMay 13, 2024 | seekingalpha.comLegend Biotech Corporation 2024 Q1 - Results - Earnings Call PresentationMay 13, 2024 | msn.comLegend Biotech Vaults on QuarterliesMay 13, 2024 | businesswire.comLegend Biotech Reports First Quarter 2024 Results and Recent HighlightsApril 23, 2024 | markets.businessinsider.comHold Rating on Legend Biotech Amidst Approval of Carvykti and Commercial Manufacturing ChallengesApril 22, 2024 | businesswire.comCARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaApril 20, 2024 | msn.comFDA requires labeling changes to CAR-T cell therapies to reflect cancer riskSee More Headlines Company Calendar Last Earnings5/13/2024Today6/08/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LEGN CUSIPN/A CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees1,800Year FoundedN/APrice Target and Rating Average Stock Price Target$81.10 High Stock Price Target$94.00 Low Stock Price Target$60.00 Potential Upside/Downside+78.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-518,250,000.00 Net Margins-135.92% Pretax Margin-182.41% Return on Equity-27.91% Return on Assets-19.49% Debt Debt-to-Equity Ratio0.25 Current Ratio5.66 Quick Ratio5.57 Sales & Book Value Annual Sales$285.14 million Price / Sales29.13 Cash FlowN/A Price / Cash FlowN/A Book Value$6.88 per share Price / Book6.62Miscellaneous Outstanding Shares182,280,000Free Float182,247,000Market Cap$8.31 billion OptionableOptionable Beta0.09 Key ExecutivesDr. Ying Huang Ph.D. (Age 51)CEO & Director Ms. Lori A. Macomber CPA (Age 53)Chief Financial Officer Mr. Doug WallaceVice President of Global OperationsDr. Guowei Fang Ph.D.Chief Scientific Officer & Head of Business DevelopmentJoanne ChoiSenior Manager of Investor RelationsMr. James Pepin J.D.General CounselDeborah WongExecutive Director of Strategic Marketing & Corporate CommunicationsMs. Elaine QianVP & Global Head of Human ResourcesDr. Yuhong Qiu Ph.D.Senior Vice President of Global Regulatory AffairsMr. Steven J. GavelSenior Vice President of Commercial Development, US & EuropeMore ExecutivesKey CompetitorsEidos TherapeuticsNASDAQ:EIDXPrincipia BiopharmaNASDAQ:PRNBAutolus TherapeuticsNASDAQ:AUTLbluebird bioNASDAQ:BLUEGenmab A/SNASDAQ:GMABView All CompetitorsInstitutional OwnershipRA Capital Management L.P.Bought 596,390 shares on 5/17/2024Ownership: 3.772%Walleye Trading LLCSold 9,500 shares on 5/17/2024Ownership: 0.000%Janus Henderson Group PLCBought 148,855 shares on 5/16/2024Ownership: 1.107%California State Teachers Retirement SystemBought 2,216 shares on 5/16/2024Ownership: 0.002%PEAK6 Investments LLCSold 4,800 shares on 5/15/2024Ownership: 0.000%View All Institutional Transactions LEGN Stock Analysis - Frequently Asked Questions Should I buy or sell Legend Biotech stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LEGN shares. View LEGN analyst ratings or view top-rated stocks. What is Legend Biotech's stock price target for 2024? 11 Wall Street research analysts have issued 12-month price targets for Legend Biotech's stock. Their LEGN share price targets range from $60.00 to $94.00. On average, they anticipate the company's stock price to reach $81.10 in the next twelve months. This suggests a possible upside of 78.0% from the stock's current price. View analysts price targets for LEGN or view top-rated stocks among Wall Street analysts. How have LEGN shares performed in 2024? Legend Biotech's stock was trading at $60.17 on January 1st, 2024. Since then, LEGN shares have decreased by 24.3% and is now trading at $45.57. View the best growth stocks for 2024 here. When is Legend Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 20th 2024. View our LEGN earnings forecast. How were Legend Biotech's earnings last quarter? Legend Biotech Co. (NASDAQ:LEGN) posted its earnings results on Monday, May, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.13. The company had revenue of $93.90 million for the quarter, compared to analysts' expectations of $143.24 million. Legend Biotech had a negative trailing twelve-month return on equity of 27.91% and a negative net margin of 135.92%. The business's quarterly revenue was up 158.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.40) EPS. What ETFs hold Legend Biotech's stock? ETFs with the largest weight of Legend Biotech (NASDAQ:LEGN) stock in their portfolio include Harbor Health Care ETF (MEDI), Global X MSCI China Health Care ETF (CHIH), Global X Genomics & Biotechnology ETF (GNOM), Matthews Emerging Markets Sustainable Future Active ETF (EMSF), Fidelity Disruptive Medicine ETF (FMED), KraneShares MSCI All China Health Care Index ETF (KURE), Tema Oncology ETF (CANC) and Virtus LifeSci Biotech Products ETF (BBP). What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY). When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,400,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Legend Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.02%), RA Capital Management L.P. (3.77%), Westfield Capital Management Co. LP (1.23%), Capital International Investors (1.20%), Janus Henderson Group PLC (1.11%) and TimesSquare Capital Management LLC (0.64%). How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LEGN) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | SponsoredProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Legend Biotech Co. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.